#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2146	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2151	288.0	0	.	n	.	0	A69G	SNP	69	69	A	322	322	G	326	G,A	192,73	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2146	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2151	288.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1703	1703	T	298	T	249	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2146	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2151	288.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1437	1437	C	344	C,T	272,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3624	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	268.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1906	1906	A	300	A	257	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3624	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	268.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2540	2540	C	364	C	294	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3624	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	268.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2614	2614	A	366	A	297	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3624	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4044	268.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3166	3166	C	309	C,T	245,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	268	folP	852	852	99.88	folP.l15.c4.ctg.1	1886	42.5	0	.	p	.	0	E151K	NONSYN	451	453	GAA	853	855	AAA	59;59;59	A;A;A	48;48;48	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	268	folP	852	852	99.88	folP.l15.c4.ctg.1	1886	42.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1084	1086	AGC	62;62;63	A;G;C	50;49;52	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	730	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3561	61.0	1	SNP	p	S91F	0	.	.	271	273	TCC	581	583	TCC	61;61;61	T,G;C;C	50,1;50;47	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	730	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3561	61.0	1	SNP	p	D95G	0	.	.	283	285	GAC	593	595	GAC	56;56;56	G,T;A,C;C	47,1;48,1;46	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	730	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3561	61.0	1	SNP	p	D95N	0	.	.	283	285	GAC	593	595	GAC	56;56;56	G,T;A,C;C	47,1;48,1;46	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	318	mtrR	633	633	100.0	mtrR.l6.c17.ctg.1	1670	57.0	1	SNP	p	G45D	0	.	.	133	135	GGC	672	674	GGC	92;92;92	G;G;C	70;69;71	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	192	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1328	42.8	0	.	n	.	0	A197.	DEL	197	197	A	745	745	A	80	A	69	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	760	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3203	70.8	1	SNP	p	D86N	0	.	.	256	258	GAC	699	701	GAC	84;84;84	G;A,C;C	68;67,1;68	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	760	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3203	70.8	1	SNP	p	S87I	0	.	.	259	261	AGT	702	704	AGT	82;82;82	A;G;T	66;69;67	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	760	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3203	70.8	1	SNP	p	S87W	0	.	.	259	261	AGT	702	704	AGT	82;82;82	A;G;T	66;69;67	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	760	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3203	70.8	1	SNP	p	S87R	0	.	.	259	261	AGT	702	704	AGT	82;82;82	A;G;T	66;69;67	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	760	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3203	70.8	1	SNP	p	S88P	0	.	.	262	264	TCC	705	707	TCC	82;82;82	T;C;C,A	69;67;68,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	700	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2955	70.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1786	1788	GGC	97;97;97	G;G;C	83;81;82	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1643	1645	GCA	83;83;83	G,T;C;A	59,1;61;61	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1646	1648	ATC	83;82;83	A,C;T;C	62,1;59;61	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1658	1660	GTG	83;82;83	G;T;G	57;57;59	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1658	1660	GTG	83;82;83	G;T;G	57;57;59	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2162	2164	ACC	64;64;64	A;C;C	52;54;54	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2216	2218	GCG	68;69;68	G;C;G	54;50;55	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2216	2218	GCG	68;69;68	G;C;G	54;50;55	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2339	2341	GGC	63;63;63	G;G;C	47;50;54	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2348	2350	GGC	59;59;59	G;G;C	46;48;48	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	556	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2918	56.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2366	2368	CTG	60;60;60	C;T;G	45;48;51	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	732	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3414	64.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1780	1782	CCG	45;45;46	C;C;G	34;34;37	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	374	porA	1146	1146	99.65	porA.l6.c4.ctg.1	2274	49.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	816	816	C	58	C	48	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	514	516	GAA	95;95;95	G;A;A	74;77;80	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	802	804	GAT	77;78;78	G,C;A;T	65,1;64;65	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	925	927	TCA	71;71;73	T,G,C;C;A	56,1,1;57;58	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1054	1056	GTC	79;79;80	G;T;C	65;61;67	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1066	1068	TCT	79;79;79	T;C;T	67;63;67	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1384	1386	GCA	90;91;89	G;C;A	70;71;69	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	1	SNP	p	G120K	1	.	.	358	360	AAG	760	762	AAG	88;88;87	A;A;G	69;68;69	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	1	SNP	p	A121D	1	.	.	361	363	GAC	763	765	GAC	87;87;88	G;A;C,G	65;70;70,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	408	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1770	67.9	1	SNP	p	D121N	0	.	.	361	363	GAC	763	765	GAC	87;87;88	G;A;C,G	65;70;70,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	1400	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5097	82.3	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2116	2118	AAT	71;72;72	A;A;T,G	57;59;55,2	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	214	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1417	45.3	1	SNP	p	V57M	1	.	.	169	171	ATG	660	662	ATG	97;97;100	A;T;G	78;79;80	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
